Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Umbilical cord mesenchymal stem cell therapy - Asia Stem Cell Regenerative Pharmaceutical

Next Previous
X
Search
Drug Profile

Umbilical cord mesenchymal stem cell therapy - Asia Stem Cell Regenerative Pharmaceutical

Alternative Names: UC-MSC infusion - Asia Stem Cell Regenerative Pharmaceutical

Latest Information Update: 14 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Asia Pharmaceuticals
  • Class Mesenchymal stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Liver cirrhosis

Most Recent Events

  • 09 Aug 2023 Asia Cell Therapeutics plans a phase I trial for Adult respiratory distress syndrome in China (IV) in August 2023 (NCT05983627)
  • 19 Jul 2023 Asia Cell Therapeutics plans a phase I trial in Ankylosing Spondylitis (Treatment-experienced) in July 2023 (IV, Injection) (NCT05962762)
  • 04 Nov 2021 Clinical trials in Liver cirrhosis (In adults) in China (IV) in November 2021 (NCT05106972)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top